Sirion Biotech, Sanofi to improve AAV capsids

By The Science Advisory Board staff writers

February 23, 2021 -- Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors for the development of effective gene therapies.

The companies, along with AAV biology scientist Dirk Grimm, PhD, of Heidelberg University Hospital, will combine proprietary technology platforms to create next generation AAV vectors. The goal of the collaboration is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.

Sanofi will leverage its expertise in virus-based vaccine and viral vector manufacturing, while Grimm will contribute AAV capsid evolution technology. Sirion will provide capabilities in AAV vector manufacturing.

Financial details of the collaboration were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?